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ABSTRACT 
Tiae initiation of DNA synthesis has been studied in quiescent primary cultures of 
fetal rat hepatocytes using defined hormones and chemically defined medium. 
Preparations  of  crystalline  insulin  (0.01-10  ~tg/ml)  or  20,000-fold  purified 
somatomedin (0.01-1 ag/ml) are stimulatory. Growth hormone (0.025 ~tg/ml) and 
hydroxycortisone (0.025  #g/ml),  3':5'-GMP!  (10  -5  M)  fail  by  themselves  to 
initiate  DNA  synthesis but added together with insulin, enhance the stimulatory 
response  by  50-100%.  Thyroid  hormones  (L-Ts,  L-T4,  7.5-30  ng/ml)  are  by 
themselves without effect, but when they are added to thyroid hormone-depleted 
serum,  the  reconstituted  mixtures  show  an  enhanced  capacity  to  initiate  DNA 
synthesis.  In  contrast,  glucagon  (0.01  #g/ml)  inhibits  the  insulin-stimulated 
response by about 50% without reducing basal  DNA synthesis rates. 
The  results  described here and  in  the  accompanying two reports indicate that 
environmental control over the initiation  of DNA synthesis is complex, and can 
involve the participation of many factors. The in vitro findings are consistent with 
the  concept  that  liver  regeneration  is  hormonally  controlled  and  raise  the 
possibility  that  alterations  of the  intrahepatic  ratio  of insulin  to  glucagon  are 
growth regulatory. 
INTRODUCTION 
Growth control studies  with  fetal rat hepatocyte 
cultures  (1-4)  indicate  that  a  macromolecular 
insulin-enriched  serum fraction, SFI (5), promotes 
initiation of DNA synthesis. This may be brought 
about, as suggested in the preceding  report (6), by 
elevating  protein synthesis  rates as a consequence 
of,  or  coupled  with  SFl-stimulated  utilization 
and/or synthesis  of L-arginine,  a  growth-regula- 
tory nutrient also  shown  to be identical with  an 
obligatory  growth-limiting  conditioning  factor 
produced by these cells  (6).  Because  insulin  was 
found  under  similar  conditions to  stimulate  the 
rate of arginine  incorporation into protein (6), it 
seemed likely that hormones involved with regulat- 
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growth hormone, and hydroxycortisone (7-10),  or 
that  hormones  with  insulin-like  activity,  such  as 
somatomedin (11-15), might also promote in vitro 
initiation  of DNA  synthesis.  Studies described  in 
this report provide direct evidence for this hypoth- 
esis, extend the concept that hepatocellular growth 
is susceptible to control by a multiplicity of serum 
factors  (5),  including  known  hormones  (16-20), 
and  raise the possibility that in vivo alterations of 
the  intrahepatic  ratio  of insulin  to  glucagon  are 
growth  regulatory. 
MATERIALS  AND  METHODS 
Reagents 
The following hormone preparations were purchased 
from Sigma Chemical Corp.  St.  Louis,  Mo.  Prolactin 
(sheep,  20-50  IU/mg),  growth  hormone  (porcine,  0.7 
IU/mg),  thyrotropic  stimulating  hormone  (bovine, 
0.5-1.0 IU/mg), insulin (bovine, 24.3 IU/mg), 3,3', 5-L- 
thyronine  (Ts) 1,  3,3',5,5'-L-thyronine,  hydroxycorti- 
sone-2 l-sodium succinate, and crystalline porcine gluca- 
gon.  Bovine  luteinizing  hormone  was  the  gift  of the 
Endocrinology Study Section, The National Institutes of 
Health,  Bethesda,  Maryland.  Purified  follicle-stimulat- 
ing hormone and FGF (21) were the generous gifts of W. 
Vale  and  D.  Gospodarowicz  (Salk  Institute),  respec- 
tively. Somatomedin C-enriched preparations (15) were 
the kind gifts of J. J. Van Wyk (20,000-fold  pure, 0.25 
units/#g,  _<0.25  microunits  immunoreactive  insulin/ 
#g). Adrenal cotticotrophic hormone (porcine, 84 units/ 
mg,  Grade  B)  was  purchased  from  Calbiochem,  San 
Diego, Calif. The following nucleotides and nucleosides 
were also obtained from Sigma: guanosine 5'-monophos- 
phoric  acid,  guanosine  2':3'-cyclic  monophosphoric 
acid,  guanosine  Y:5'-cyclic monophosphoric  acid,  N ~, 
O2-dibutyryl  guanosine  3':5'-cyclic  monophosphoric 
acid,  N%O~-dibutyryl  adenosine  3':5'-cyclic  mono- 
phosphoric  acid (Grade  II), and guanosine. Tissue cul- 
ture supplies  were obtained as previously described (1 
~,4bbreviations  used in  this paper: ACTH,  adrenal 
corticotrophic hormone;  3':5'-AMP!, N e,O2-dibutyryl 
adenosine  3':5'-cyclic  monophosphoric  acid;  dbY:5'- 
GMP!,  N20~-dibutyryl  guanosine  3':5'-cyclic  mono- 
phosphoric acid; dFBS, dialyzed fetal bovine serum (3); 
FGF, 3T3-fibroblast growth  factor (21);  FSH, follicle- 
stimulating  hormone;  GH,  growth  hormone;  GMP, 
guanosine 5'-monophosphoric acid; 2':3'-GMP!, guano- 
sine 2': Y-cyclic monophosphoric acid; Y: 5'-GMP!, gua- 
nosine  Y:5'-cyclic monophosphoric acid; [3H]dT,  CHa- 
[SH]thymidine;  LH, luteinizing hormone; L-Ts, 3,3', 5-L- 
thyronine  (tri-iodothyronine);  L-T4, 3,3',5,5'-L-thyro- 
nine. 
5).  CHs-[3H]thymidine  (sp  act  20  Ci/mmol)  was 
purchased  from New England  Nuclear,  Boston,  Mass. 
Insulin  radioimmunoassay  kits  were  obtained  from 
Schwarz/Mann Div., Becton, Dickinson & Co., Orange- 
burg, N. Y. 
Assays 
DNA synthesis  initiation assays  were performed with 
9-1 l-day old quiescent cultures.  1-2% of the cells are in 
S-phase  as  judged  by  autoradiography  following  a 
12-24-h  pulse  with  [SH]dT  established  as  previously 
described  (4,  6).  Unless  noted,  all  experiments  were 
conducted  by  addition  to  the  cultures  of 2  ml  fresh, 
arginine-supplemented (0.4  mM) medium together with 
substances  to  be  tested  (0.1-0.3  ml),  the  indicated 
concentrations of which represent the final concentration 
initially present  in  the  medium.  SubstancEs  for testing 
were prepared  fresh  before use.  All hormone dilutions 
were  made  using  plastic  pipettes  and  tubes  (Falcon 
Plastics,  Div.  of  B.-D.  Laboratories,  Los  Angeles, 
Calif.). 
Preparation of Thyroid Hormone- 
Free Serum 
Dialyzed  fetal  bovine serum  was  alkalinized  to  pH 
13.0 with  12  M  NaOH  to dissociate thyroid hormone- 
protein  complexes,  and  dextran-coated  charcoal  was 
added (6.6 g Norite A per 100 ml serum) to adsorb free 
hormone (22).  The supernate  was  collected and the pH 
adjusted  to  8.6  with 6 N  HC1. This material was  then 
centrifuged  three  times  (Ivan  Sorvall,  Inc,,  Newtown, 
Conn.,  4°C,  10  min,  20,000  g)  to  remove  charcoal, 
dialyzed  by  standard  procedures  ~s.  isotonic  NaC1, 
sterilized  by  filtration  (0.45-,m  Nalgene  filter; Nalge 
Co.,  Nalgene  Labware  Div.,  Rochester,  N.  Y.),  and 
stored at -20°C. This procedure rethoved >99% of the 
serum tetraiodothyronine (initial concentration ca.  14.5 
,g  %) as determined  chemically by a  T4-protein  bind- 
ing assay (23),  and  >99% of the~ serum L-Ts,  as deter- 
mined by the recovery of radioactivity associated with 
L-Ts after incubation of dFBS with  i  ×  105 cpm L-T~ 
(Abbott Scientific Products  Div.,  Abbott  Laboratories, 
South  Pasadena,  Calif.,  365  #Ci/~l,  5  /zg/ml)  and 
subsequent  extraction as described above. 
RESULTS 
Hormonal  initiation  of fetal hePatoceUular  DNA 
synthesis in chemically defined medium is shown in 
Figs.  1 and 2. Under these conditions, as indicated 
previously (6), greater than 90% of the responding 
cell population  is derived from Go or early G1. 
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FIGURE  1  Initiation  of DNA  synthesis by  insulin  in 
chemically  defined  medium.  (A)  Time  course.  Fresh 
medium containing insulin  (O--@, 0.01 #g/m1; O---II, 
10.0 #g/ml), 10% dFBS (r-i_l-q),  or 0.2 ml isotonic NaCI 
(hexagons) was added to quiescent cultures (0.5  ×  105 
cells/dish). At varying times, [SH]dT (I.25 #Ci/ml, 3 × 
10 -e  M  dT)  was added,  and  after a  2-h  pulse  (points 
shown) the incorporation of TCA-precipitable radioac- 
tivity  determined.  Abscissa:  time  (hours)  after  fresh 
medium  change.  Ordinate:  counts  per  minute  pH]dT 
incorporated per culture per 2-h pulse. (B, inset) Insulin 
or  serum-exposure times  required  to  stimulate  DNA 
synthesis. Fresh medium containing insulin (10 #g/ml) or 
10% vol/vol dFBS was added to quiescent cultures (time 
zero  [cpm/culture/2-h pulse]  ~  80). At  4,  8,  or  12  h 
thereafter, the dishes were washed twice with insulin-free 
and  serum-free medium and  replaced with similar me- 
dium.  Control dishes received  continuous exposure.  All 
cultures were pulse labeled  and assayed as in Fig.  1 A. 
Absolute incorporation rates (100% maximal response) 
for dishes receiving  continuous exposure were:  insulin, 
240;  10%  serum,  1,640. Abscissa:  replacement  time 
(hours),  i.e.,  time  at  which  dishes  were  washed  and 
replaced with fresh insulin-free  and serum-free medium. 
Ordinate: percent of maximal response. 
FIGURE  2  Quantitative initiation of DNA synthesis by 
insulin  and somatomedin; enhancement by growth hor- 
mone  and  hydroxycortisone and  by  L-arginine.  Fresh 
medium  containing 0.4  mM  L-arginine  was  added  to 
quiescent cultures (0.29  ×  105  cells/dish) together with 
insulin  (D---D) or somatomedin (Q .....  ~) at the con- 
centrations  (#g/ml)  indicated  by  the  abscissa.  These 
cultures  were  incubated  for  6  h  with  [aH]dT  (1.25 
#Ci/ml) between 18 and 24 h later, and the proportion of 
DNA-synthesizing  cells was determined by autoradiogra- 
phy  (l,000  cells/dish scored [6])  and  indicated by the 
right ordinate. Similar experimedts were conducted with 
the following  additions: growth hormone (0.025 #g/ml) 
and  hydroxycortisone-succinate (0.025  #g/ml),  ([]); 
growth hormone (0.025 #g/ml) or hydroxycortisone-suc- 
cinate  (0.025 #g/ml),  (I-b-I); growth  hormone  (0.025 
#g/ml), hydroxycortisone-succinate (0.025 #g/ml), and 
insulin  (0.05 #g/ml),  (I-c-I); growth  hormone  (0.025 
#g/ml), hydroxycortisone-succinate (0.025 #g/ml), and 
insulin  (1.0 #g/ml), (~']);and  10%  vol/vol dFBS (not 
shown,  =  60%). In  separate experiments (solid  lines), 
fresh  medium  containing  L-arginine  (solid  hexagons, 
zero; O--tt, 0.004 mM; and A--A, 0.4 mM) and insulin 
was added at varying concentrations  to quiescent cultures 
as  indicated on  the abscissa. These cultures were pulse 
labeled with [OH]dT (1.25 #Ci/ml, 3 x  10  e dT) between 
22  and  24  h  and  the  radioactivity  incorporated  in 
TCA-precipitable material  per culture  was determined 
(left  ordinate). 
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Hormone Addition 
Preparations of crystalline bovine insulin (0.01 
/~g/ml  and  10.0  #g/ml),  or 20,000-fold  purified, 
insulin-deficient  somatomedin  (1  ~tg/ml)  were 
added  to  quiescent  cultures  together  with  fresh 
medium. The kinetics of [SH]dT incorporation into 
DNA (2) were measured for 0-43 h and the results, 
for the insulin addition, are shown in Fig. 1 A. It is 
seen that a  10-h lag period ensued, after which the 
initial incorporation rates, at 10  12-h, increased in 
proportion to the final concentrations of hormone 
initially  added  to  the  medium.  DNA  synthesis 
rates  remained  elevated  in  cultures  which  had 
received high doses, but not low doses of insulin, 
suggesting  that'  additional  cells  were  being  re- 
cruited to synthesize DNA (4, 6). Similar kinetics 
were  observed with  cultures that  received soma- 
tomedin (1  ~g/ml, not shown).  As expected from 
previous observations (4, 6), DNA synthesis rates 
were  stimulated  slightly  in  the  absence  of hor- 
mones,  a  response which  represented under these 
conditions  <1  2%  increase  in  the  basal  nuclear 
labeling index, as determined by autoradiography. 
Commitment  to Synthesize DNA 
To  determine  whether  continuous  exposure to 
insulin  or  to  10%  vol/vol  dFBS-containing me- 
dium was required to obtain maximal DNA syn- 
thesis rates, quiescent cultures were incubated for 
varying periods of time (0-12 h),  after which the 
medium was changed to fresh, hormone-free and 
serum-free  medium.  Cultures  were  then  pulse 
labeled with [3H]dT (22-24 h) and the quantity of 
label incorporated into DNA was determined. The 
results, shown  in  Fig.  1 B,  indicated that  serum 
was more efficient than insulin in "committing" a 
cell population to synthesize DNA after either 8 or 
12  h  of  continuous  exposure.  In  both  cases, 
however, about 30% of the maximal DNA synthe- 
sis  occurred  with  incubation times of 4-8  h,  but 
little DNA synthesis was detectable after incuba- 
tion  times  of  4  h.  Similar  results  using  serum 
additions have  been  reported with  3T3  cells (24) 
and secondary chick embryo (25) fibroblasts. 
Recruitment of DNA-Synthesizing  Ceils 
Autoradiographic measurements (18-24 h post- 
addition) indicated that  the  stimulation of DNA 
synthesis  by  preparations  of  both  insulin  and 
somatomedin resulted from the initiation of DNA 
synthesis in a small but significant fraction of the 
cells. This is shown in Fig. 2. 
Quantitative  comparisons  between  efficiencies 
of stimulation of each of the hormone preparations 
cannot be made until homogeneously pure soma- 
tomedin  C  has  been  obtained.  Dose-response 
curves (Fig. 2)  indicated that  neither of the hor- 
mone  preparations  was  capable  of replacing se- 
rum,  which  would  imply that  additional factors, 
perhaps  specific carriers (5,  26),  are  required to 
obtain  a  maximal  response.  The  presence  of  1 
mg/ml crystalline albumin did  not  enhance  hor- 
monal  stimulation,  so  that  adsorption  to  the 
plastic tissue culture dish would be unlikely to have 
caused the high requirement. Alternatively, hetero- 
geneity  of the  responding  cell population .might 
explain these  observations, with  respect to either 
cell type or position in G1 (25). These possibilities 
seem  unlikely,  however,  owing  to  the  selection 
procedures employed (1, 3, 6), and to the observa- 
tion (Fig. 2) that increasing amounts of hormone 
increased the nuclear labeling index which would 
be expected from a noncommitted, Go cell popula- 
tion  responding to  increasing amounts  of serum 
(25).  Finally,  in  considering  the  possibility that 
crystalline insulin contains a  minor contaminant, 
preliminary  use  of  guinea  pig  anti-insulin  an- 
tiserum, the generous gift of E. A. Arquilla (Uni- 
versity  of  California  at  Irvine),  in  attempts  to 
block  insulin-stimulated  DNA  synthesis  has 
been inconclusive owing to the simultaneous pres- 
ence  in  unfractionated  normal guinea  pig serum 
of possibly specific (5) inhibitory material. 
Visual inspection  of the cultures by phase  mi- 
croscopy revealed the presence of mitotic figures 
only after hormone  addition and  no  sooner than 
23-24 h. Scarcity of these dividing cells, however, 
made  difficult  the  direct  attempts  to  determine 
whether  mitotic cells had  previously synthesized 
DNA, although the kinetics of DNA synthesis seen 
in  Fig.  1 A  would indirectly lend support to this 
interpretation. 
Enhancement of Insulin-Initiated 
DNA Synthesis 
Stimulation of insulin-initiated DNA synthesis 
was  enhanced  synergistically  by  the  additional 
presence of 0.1-1.0% vol/vol dialyzed fetal bovine 
serum  as  shown  by  the  increasing  slopes of the 
dose-response curves in Fig. 3. Because the concen- 
trations of immunoreactive insulin (1-10 pg) pres- 
ent in the~e concentrations of sera failed to stimu- 
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FIGURE  3  Serum  enhancement  of  insulin-initiated 
DNA synthesis. Fresh  medium containing varying con- 
centrations of insulin (0-10 #g/ml) and  supplemented 
with either isotonic saline (O--II, 0.2 ml/dish), or dFBS 
(A--,L, 0.1%, vol/vol containing 1-2 pg immunoreactive 
insulin;  O--~I~,  1.0%, vol/vol  containing  10-20  pg 
immunoreactive  insulin; I1--11,  10%, vol/vol containing 
ca.  300 pg immunoreactive  insulin was added to quies- 
cent cultures  (0.53  ×  l0  s cells/dish).  All cultures were 
pulse labeled with [aH]dT (1.25 #Ci/ml, 3 ×  10  e M dT) 
between 22 and 24 h and the radioactivity incorporated 
into  TCA-precipitable material per culture  was deter- 
mined. Abscissa: insulin added to culture medium (~g/ 
ml). Ordinate:  cpm [3H]dT culture. 
late detectable DNA synthesis (Fig. 2), the results 
of Fig.  3  further  indicated that  additional serum 
factors are involved with initiating DNA synthesis 
(5,  27)  which,  if present,  might  also  function  to 
reduce the insulin requirement. 
In  regard  to  this  possibility, combinations  of 
somatomedin  and  insulin  (#g/ml,  respectively, 
I : 1,  1 : 10, and  10: !), failed to produce synergistic 
effects. However, the combined addition of prepa- 
rations  of GH  (0.025  #g/ml)  and  hydroxycorti- 
sone (0.025 #g/ml), previously reported to stimu- 
late,  in  the  presence  of insulin, protein synthesis 
in the isolated perfused liver (7, 8), lowered the in- 
sulin  requirement  for  initiating  DNA  synthesis 
and synergistically enhanced by about 50% the in- 
sulin-stimulated response. This is shown in Fig. 2, 
boxes C  and D, respectively. GH and hydroxycor- 
tisone  were  not  stimulatory  when  added  either 
together  (0.025  #g/ml,  Fig.  2,  box  A)  or separ- 
ately  (0.025  #g/ml,  Fig.  2,  box  B).  Higher con- 
centrations  of  hydroxycortisone  inhibited  DNA 
synthesis (>_ 1 #g/ml),  which  is qualitatively and 
quantitatively consistent with results observed for 
in vivo hepatocellular growth studies (28). 
In light of recent reports which have suggested 
that cyclic guanosine nucleotides may be involved 
with  growth  stimulation  of  mammalian  cells 
(29-31),  it  was  of interest to  determine whether 
one  or  more  of these  compounds  could  replace 
insulin. The results of these experiments are shown 
in Fig. 4.  The stimulatory effects of insulin could 
not  be  replaced  by  any  one  of the  compounds 
tested(Y: 5'-GMP!, N 2, O2-dibutyryl 3': 5'-GMP!, 
2': Y-GMP!) including GMP  and  guanosine (not 
shown) within a concentration range of 10-7-10 -8 
M.  In the  presence of excess insulin (10 #g/ml), 
however, the rate of DNA synthesis was enhanced 
optimally  at  10 -5  M  by  3':5'-GMP!  (100%), 
N~,O2-dibutyryl  3':5'-GMP!  (60%),  and  2':3'- 
GMP!  (50%).  No prior estimate of the extent of 
contamination  with  butyric acid of the dibutyryl 
compound was made which might account for the 
reduced enhancing effect observed with this com- 
pound. At present, this appears an unlikely possi- 
bility  because  suppression  of  insulin-stimulated 
DNA  synthesis  with  derivatives  not  containing 
dibutyryl  groups  also  was  observed  at  higher 
concentrations (10 -4 M). 
The  efficiency of insulin-stimulated DNA  syn- 
thesis also was enhanced by L-~frginine, as shown in 
Fig. 2, much the same as the interaction between 
serum and L-arginine was'shown to be a determi- 
nant  of DNA  synthesis capacity in these cultures 
(6).  Stimulation  of DNA  synthesis  required  the 
simultaneous addition of insulin (or SFI (5)) and 
L-arginine because in separate experiments it was 
found that pretreatment of the cultures with argi- 
nine-free,  insulin:supplemented,  or  10%  vol/vol 
SFI-supplemented medium for varying periods of 
time (0-24  h) before  arginine-addition (0.4 raM) 
failed to shorten the  10-h onset time. 
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FIGURE 4  Cyclic guanosine nucleotide enhancement of 
insulin-initiated  DNA synthesis. Fresh medium contain- 
ing varying  concentrations  of cyclic guanosine  nucleo- 
tides  (II--L  guanosine  2':Y-cyclic monophosphoric 
acid;  A--A,  N~,O2-dibutyryl  guanosine  3':5'-cyclic 
monophosphoric  acid;  0--0,  guanosine  3':5'-cyclic 
monophosphoric  acid) with or without insulin (0.1 #g/ 
ml) was added to quiescent cultures  (0.39  ×  l0  s cells/ 
dish). All cultures were pulse labeled with [3H]dT (1.25 
#Ci/ml, 3 ×  10  -e M dT) between 22 and 24 h and the 
radioactivity incorporated  into TCA-precipitable mate- 
rial per culture  was determined.  Abscissa: cpm [3H]dT 
per  culture.  Ordinate:  molar  concentration  of cyclic 
nucleotide. 
A spectrum of additional pituitary-derived poly- 
peptide hormones was also tested (0.01-1.0 #g/ml) 
for  DNA  synthesis-stimulating  capacity,  using 
chemically defined complete media and quiescent 
cultures.  Hormones  tested  included  LH,  TSH, 
FSH,  ACTH,  prolactin,  and  a  recently purified 
fibroblast growth factor, FGF (21). None of these 
hormones  was  found  to  stimulate or to enhance 
insulin-stimulated DNA synthesis. 
DNA Synthesis Requirement for 
Thyroid Hormones 
In view of past (16,  17) and recent studies (20) 
implicating thyroid-derived hormones  in  in  vivo 
hepatocellular growth control, as well as recent in 
vitro studies demonstrating growth-controlling ef- 
fects of thyroid hormones with cultured pituitary 
tumor cells (32, 33), it was of interest to determine 
whether  or not  cultured  fetal hepatocytes would 
also demonstrate a similar growth requirement. 
In  preliminary  experiments  using  chemically 
defined complete media, little stimulation of DNA 
synthesis was observed (Table I) with either L-Ts 
or  L-T,  (_<20% above control and  therefore  not 
statistically significant under the conditions of the 
assays used). Combinations of L-Ts and glucagon 
(20) (0.01-1.0 #g/ml) similarly failed to stimulate 
DNA  synthesis.  In  addition,  insulin-stimulated 
DNA synthesis was not enhanced by L-Ts.  How- 
ever, if either L-Ts (7.5-15 ng/ml), or L-T, (10-30 
ng/ml) was  added to  quiescent  cultures together 
with  thyroid  hormone-free  dFBS  (2.5-15%  vol/ 
vol), then 60  70% of the DNA synthesis-stimulat- 
ing  capacity  was  restored,  with  L-Ts  appearing 
about twice as efficient as L-T,. This also is shown 
in Table I. 
Inhibition of Insulin-Stimulated DNA 
Synthesis by Glucagon 
With regard to the catabolic effects of glucagon 
(34),  many  of which  antagonize insulin-mediated 
functions  (I0,  35-37),  as  well  as  recent  surgical 
studies implicating glucagon as a possible circulat- 
ing inhibitor of bepatocellular proliferation (19), it 
was  of interest to determine the direct effects of 
glucagon upon the initiation of DNA synthesis in 
cultured fetal rat hepatocytes. 
Chemically  defined  complete  medium  supple- 
mented  with  insulin  (10.0  #g/ml),  and  varying 
amounts  of porcine  glucagon  (0.001  #g/m[-l.0 
#g/ml) were added together to quiescent cultures, 
and  the  rate  of  DNA  synthesis  was  measured 
22-24-h  later. The results are shown in Fig. 5.  It 
may be seen that the basal rate of [SH]dT incorpo- 
ration  into  DNA  was  unaffected  by  glucagon 
throughout  the  concentration  range tested.  Inde- 
pendent measurements (trypan-blue exclusion and 
cell attachment [3]) also showed that no detectable 
cytotoxic  effects  had  occurred  as  a  result  of 
exposure to the hormone for 24  h.  However, the 
stimulatory  effect  of  insulin  was  suppressed  by 
about  50%  as the concentration  of glucagon was 
increased (>2  ×  10 -9  M).  Autoradiography also 
revealed diminished nuclear  labeling: basal  level 
(2%);  insulin,  10.0  #g/ml  (10.3%);  insulin,  10.0 
#g/ml plus glucagon, 0.5 #g/ml (5.8%). 
Ne,O~-dibutyryl  3':5'-AMP!  (> 10-'  M)  was 
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Stimulation of DNA synthesis in fetal rat hepatocyte cultures  by thyroid hormone-depleted  fetal bovine  serum 
reconstituted  with L-T5 or L-T4 
Percent vol/vol initial serum 
L-T,  L-T,  0  2.5  5.0  15.0 
ng/ml  ng/ml 
0  0  350  900  1,750  2,200 
0  0  340  390  490  940 
0  10  350  590  ND  1,100 
0  30  370  780  ND  1,540 
7.5  0  390  ND  1,000  ND 
15.0  0  415  ND  1,270  ND 
Untreated dFBS 
Depleted dFBS 
Fetal rat hepatocytes were prepared for DNA synthesis initiation assays, and thyroid hormone-depleted dFBS (,4 ~5o = 
22/ml) was  prepared  as described  in  Materials and  Methods.  The additions  were made to  l 1-day  old quiescent 
cultures (0.62  ×  105 cells/30-mm diameter dish) as 0.1-0.3-ml aliquots in 2 ml fresh medium supplemented with 0.4 
mM L-arginine. The values given represent the rate of DNA synthesis  (cpm [aH]dT per culture) as determined by 2-h 
pulse-labeling  22-24 h later with [5H]dT (1.25 pCi/ml, 3 ×  10 -6 M dT). The amount ofA~80 nm material present in 
untreated dFBS was 25.1/ml. 
ND, not determined. 
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Inhibition of insulin-initiated DNA synthesis 
by glucagon. Fresh medium containing varying concen- 
trations  of  glucagon  (0-1.0  pg/ml)  with  or  without 
insulin  (10 pg/ml) was added  to quiescent cultures (0.57 
×  105  cells/dish). All cultures  were  pulse labeled  with 
[3H]dT (1.25"pCi/ml, 3 ×  10  -5 M tiT) between 22 and 24 
h and the radioactivity incorporated into TCA-precipita- 
ble  material  per  culture  was  determined.  Abscissa: 
glucagon  added  to  culture  medium  (pg/ml).  Ordinate: 
cpm [SH]dT incorporated per culture per 2-h pulse. 
found  to  inhibit  both  insulin-stimulated  DNA 
synthesis  and  the  basal  DNA  synthesis  rate,  an 
expected  finding  in  view  of the  known  cytotoxic 
effects of this drug  (38),  as well as its capacity to 
inhibit  thymidine  transport  (39).  At high concen- 
trations,  glucagon  (10.0  pg/ml)  also  reduced 
(50-80%) the basal DNA synthesis rate. Therefore, 
it may be that  in vitro suppression  by glucagon (3 
×  10-" M) of insulin-stimulated initiation of DNA 
synthesis is mediated  by intracellular cyclic AMP 
because: (a) these cultured cells do show increased 
intraceUular cyclic AMP  levels within  1-2 min in 
response  to  glucagon  (H.  Leffert  and  W.  Seifert, 
unpublished  observations); and (b) in growth cycle 
studies  (5),  intracellular  cyclic  AMP  levels  are 
inversely  correlated  with  lag,  log,  and  stationary 
growth  states  (H.  Leffert  and  W.  Seifert,  unpub- 
lished observations). 
Physiological  concentrations  (10 -8  M)  of  L- 
epinephrine,  suggested  to  act  upon  the  liver via 
cyclic AMP-mediated reactions (40), although less 
efficiently  than  glucagon  (41),  did  not  inhibit 
insulin-stimulated  DNA  synthesis  in  this  culture 
system.  Much  higher  concentrations  (10  -(M) 
were  required  to  produce  effects similar to  those 
seen with toxic levels of cyclic AMP  (10 -~ M). 
DISCUSSION 
The initiation of DNA synthesis by serum factors 
in quiescent fetal rat bepatocyte cultures has been 
shown,  in  this  report,  to  involve  at  least  six 
hormones.  Included  in  this  group  are  insulin, 
growth  hormone,  hydroxycortisone,  the  thyroid 
hormones L-Ta and L-T4, enriched preparations  of 
somatomedin-C(15),  and glucagon. 
Two  main  conclusions  are  to  be  derived  from 
these  studies:  First,  an  interaction  among  many 
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DNA synthesis. This was indicated by the observa- 
tion that although none of the hormones detectably 
promoted significant initiation of DNA synthesis, 
except for microgram levels of insulin and soma- 
tomedin,  conditions could  be  foundwhereby  in- 
sulin effects were enhanced.  For example, in the 
presence of nanogram  levels of growth hormone 
and  hydroxycortisone (Fig. 2,  box C), nanogram 
levels  of  insulin  were  found  to  stimulate  DNA 
synthesis  sixfold  over background,  but  in  the 
absence  of  these  "permissive"  hormones,  200 
times as much  insulin  was  required to  achieve a 
similar effect. 
Enhancement  of insulin-stimulated DNA  syn- 
thesis  also  was  brought  about by  10 -5  M  3':5'- 
GMP!  (Fig.  4).  In  contrast,  glucagon  (1  1000 
ng/ml)  had  neither  detectable  stimulatory nor 
inhibitory effects, but when combined with insulin, 
partially inhibited (50%) the stimulation of DNA 
synthesis (Fig. 5). 5 A  further example of multiple 
serum  factor  interactions  is  suggested  from  the 
finding that thyroid hormones (L-Ts, L-T4) were by 
themselves nonstimulatory at nanogram levels, but 
were stimulatory in the presence of the appropriate 
additional  serum  factors  Table  I.  The  "permis- 
sive" factor(s) which thyroid hormones apparently 
require for expression of their DNA synthesis-pro- 
moting capacity remain to be determined. 
Second,  if  a  multiplicity of  factors  including 
those yet to be identified (5, 6) controls initiation 
processes,  then  the  problem  of  initiating  DNA 
synthesis  becomes  a  problem  in  understanding 
concerted hormone action (42-50). 
For  example,  some  evidence  with  this  system 
suggests that  both  insulin  and  SFI  (5)  stimulate 
increased utilization and/or synthesis of a growth- 
limiting  nutrient  (arginine)  required  to  increase 
protein synthesis rates which precede the induction 
of DNA  synthesis (6).  However,  as  indicated in 
this  report,  since pretreatments  of the  cells with 
either insulin or SFI fail to reduce the onset time 
for DNA synthesis, since insulin or SFI must be 
added simultaneously, together with arginine, and 
since only insulin or insulin-like material (soma- 
tomedin [ l 1-15]) appear to be the most limiting of 
the hormones studied thus far, one of the earliest 
prereplicative events  would  appear  to  be  an  in- 
2These  observations  have  been  confirmed  in  similar 
studies carried out by:.Paul, D., and S. Walter. 1974. J. 
Cell. Physiol.  Submitted for publication. 
teraction  between  arginine,  insulin,  and  the  cell 
membrane  (42,  43,  51,  52).  Whether  or not  this 
proposed  interaction  is  modulated  (53)  by  addi- 
tional hormones  including those described in this 
report  remains  to  be  determined,  although  with 
regard to recent reports (37,  54), the results here 
suggest a possible link between thyroid hormones, 
the  regulation  of  cholesterol  metabolism  (55), 
membrane  permeability  changes  (56-58),  and 
DNA synthesis. 
In light of the above conclusions, it is puzzling 
that only a  fraction of the cells responds to either 
single or multiple hormone additions. The evidence 
tends to argue against a trivial explanation such as 
monohormonally  responsive (nonparenchymal) 
subpopulations (see Results), (3). Alternatively, if 
heterogeneity exists amongst Go cells in regard to 
their steady state interactions and/or "preactiva- 
tion" with or by any one of a set of limiting serum 
factors,  then  this could  explain the  "quantized" 
nature  of  the  response.  This  interpretation  is 
consistent  with  similar in  vitro  findings  using  a 
cloned 3T3-fibroblast cell line (59), and would help 
to clarify the observed differences between serum 
and insulin in regard to commitment-time kinetics 
(Fig.  1  B).  This  interpretation  is  also consistent 
with  in  vivo  evidence  that  L-T~ can  preactivate 
quiescent  liver,  assuming  that  the  hormone  acts 
directly, in preparation for subsequent stimulation 
(20). However, differences in the cellular topology 
of  cultured  hepatocytes,  the  more  peripherally 
situated cells (1) being more available or sensitive 
to  interactions  with  one  or  more  specific  hor- 
mones,  remains  an  additional  explanation  (60). 
This possibility has been ruled out, however, in the 
fibroblast system (59). 
Finally, it is of interest to consider whether or 
not the results described for this hepatocyte system 
(5, 6) have any bearing upon the problem of liver 
regeneration. Of possible significance is the finding 
that  a  partially purified,  insulin-enriched  serum 
fraction (SFI) which promotes DNA synthesis in 
vitro also was found to promote some detectable 
hepatocellular  DNA  synthesis  in  vivo  (5).  In 
addition,  thyroid  hormones  which  have  been 
shown  to  promote  in  vivo hepatocellular growth 
(16, 17, 20) also appear to play a role in the in vitro 
control of DNA  synthesis in  this  system.  More- 
over,  although  ablation  of  no  single  endocrine 
gland has  yet abolished liver regeneration, those 
ablations  examined  thus  far,  including  para- 
thyroidectomy  (61),  hypophysectomy  (62),  and 
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sponse. So, too, does partial chemical ablation by 
alloxan  of  pancreatic  ~3  cells  (64).  These  results 
taken  together  would  all  be  consistent  with  a 
"multiple  factor"  hypothesis?  Furthermore,  al- 
though  recent  in  vivo  studies  implicate  systemi- 
cally administered glucagon as a  stimulatory hor- 
mone (20), in contrast to other reports (19) as well 
as the results described here, the in vivo action of 
glucagon  and thyroid hormones also could be one 
of indirectly stimulating insulin release (68-71). I n 
this  regard,  recent  in  vivo  studies  support  the 
concept  that  both  insulin  and  glucagon  are  in- 
volved with hepatocellular growth (72) in a manner 
consistent with the results described in this in vitro 
system (Fig.  5). 
The  possibility  is  suggested,  therefore,  that 
alterations of the intrahepatic ratio, or balance, of 
insulin  to  glucagon  (I:G)  may  play  a  crucial, 
regulatory role in hepatocellular growth processes. 
The "reversal" of a  low I:G, such as that obtained 
by the administration of insulin to alloxan-diabetic 
rats (64) or of amino acids to protein-starved rats 
(73, 74), could set into motion additional endocrine 
and  hepatic  changes  (75-78)  required  to  initiate 
DNA  synthesis in the liver. 
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